Eric M. Flanders Chair in Palliative Medicine, McGill University
Director of Palliative Care, McGill University
Chief of the Marjorie & Gerald Bronfman Palliative Care Division, Jewish General Hospital Dr Lapointe is a family physician by training, who became involved in caring for the terminally ill in the mid-1980s while working with persons living with AIDS / HIV. He currently leads the palliative care program at McGill University and at the Jewish General Hospital.
He is active in the search for novel analgesics, including his current work as co-principal investigator on the clinical evaluation of tetrodotoxin (a toxin found in the fugu fish) for cancer pain. He has also collaborated via the Clinical Research Unit of the Segal Cancer Centre on many multi-centre evaluations of innovative drugs for cancer pain. He is interested in the quality of life of people living with cancer and of their informal caregivers. He is currently collaborating with Dr. Robin Cohen on a major research initiative aimed at evaluating interventions in support of informal caregivers.
He is the past-President of the Palliative Care Association of Québec and of the Canadian Hospice Palliative Care Association (CHPCA). He is the Chair of the International Cooperation Committee of the CHPCA and is a member of the Board of the Canadian Society of Palliative Care Physicians. His contributions to the field of palliative care have been recognized with the 2010 Medal of Honour from the Réseau de soins palliatifs du Québec, the 2007 CHPCA Award of Excellence, and, in 2002, with Her Majesty Queen Elizabeth II’s Golden Jubilee Medal. Recent publications
Hagen
NA, Lapointe B, Ong-Lam M, Dubuc B, Walde D, Gagnon B, Love R, Goel
R, Hawley P, Ho Ngoc A, du Souich P. A Multicentre open-label safety
and efficacy study of Tetrodotoxin for cancer pain. Current
Oncology, 2011, Volume 18, Number 3, 109-116.
Neil
A. Hagen, Patrick du Souich, Bernard Lapointe, May Ong-Lam, David
Walde, Robin
Love, Anh Ho Ngoc and on behalf of the Canadian Study Group.
Tetrodotoxin for
moderate to severe cancer pain : A randomized, double blind,
parallel design multicenter
study. Journal of Pain and Symptom Management, 2008, Volume 35, Issue
4, 420-429.
Hagen
NA, Fisher KM, Lapointe B, du Souich P, Chary S, Moulin D, Sellers E,
NgocAH,
on behalf of the Canadian Tetrodotoxin Study Group. An Open-Label,
Multi-DoseEfficacy
and Safety Study of Intramuscular Tetrodotoxin in Patients with
Severe CancerRelated
Pain. J Pain Symptom Manage. 2007; 34: 171-182 |